复方GLP-1及双重GIP/GLP-1受体激动剂:美国糖尿病协会声明
美国糖尿病协会发布声明,针对GLP-1受体激动剂和双重GIP/GLP-1受体激动剂药物短缺期间及短缺缓解后仍被大力营销的复方制剂,指导医疗专业人员和糖尿病和/或肥胖患者促进最佳护理和用药安全。
要点
- GLP-1受体激动剂和双重GIP/GLP-1受体激动剂的使用在過去几年大幅增加,用于治疗2型糖尿病和肥胖。
- 药物需求增加导致GLP-1受体激动剂和双重GIP/GLP-1受体激动剂药物出现暂时性产品短缺。
- 短缺部分导致实体生产和营销绕过监管措施的复方制剂,引发安全性、质量和有效性担忧。
核心结论
- 美国糖尿病协会的声明旨在指导医疗专业人员和糖尿病和/或肥胖患者在药物不可用的情况下促进最佳护理和用药安全。
研究设计与样本
- 美国糖尿病协会发布的声明。
主要发现
- GLP-1受体激动剂和双重GIP/GLP-1受体激动剂的使用在過去几年大幅增加,用于治疗2型糖尿病和肥胖。
- 药物需求增加导致GLP-1受体激动剂和双重GIP/GLP-1受体激动剂药物出现暂时性产品短缺。
- 短缺部分导致实体生产和营销绕过监管措施的复方制剂,引发安全性、质量和有效性担忧。
- 即使短缺解决,复方GLP-1受体激动剂和GIP/GLP-1受体激动剂产品仍被大力营销给糖尿病和肥胖患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (GIP/GLP-1 RA) classes has increased substantially over the past several years for treating type 2 diabetes and obesity. Increased demand for these pharmacotherapies has resulted in temporary product shortages for both GLP-1 RA and dual GIP/GLP-1 RA medications. These shortages, in part, have led to entities producing and marketing compounded formulations that bypass regulatory measures, raising safety, quality, and efficacy concerns. Even as shortages resolve, compounded GLP-1 RA and GIP/GLP-1 RA products continue to be heavily marketed to people with diabetes and obesity. The purpose of this statement by the American Diabetes Association is to guide health care professionals and people with diabetes and/or obesity in these circumstances of medication unavailability to promote optimal care and medication use safety.
引用
- Neumiller JJ, Bajaj M, Bannuru RR, et al. Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care. 2025. PMID: 39620926. doi:10.2337/dci24-0091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。